Chromatogr.A 1123,225–232(2006).
non-porousreversed-phasehighperformanceliquidchromatographycolumns.
influenzavirusconstituentsinmonovalentandmultivalentpreparationsusin
91. Garcia-Canas,V.,Lorbetskie,B.&Girard,M.Rapidandselectivecharacterization
chromatographyand fluorescencedetection. Anal.Chem. 79,3164–3172(2007
proteinsincommercialvaccinesusingtwo-dimensionalhigh-performanceliqui
90. Garcia-Canas, V. et al. Selective and quantitative detection of influenza viru
vaccines. J.AllergyClin.Immunol. 125,1412–1413(2010).authorreply1413-141
89. Li,J.T.,Rank,M.A.,Squillace,D.L.&Kita,H.Ovalbumincontentofinfluenz
1630–1637(2019).
inactivationmethodsoninfluenzavirionstooptimize. Vaccin.Prod.Vaccin. 3
88. Herrera-Rodriguez, J. et al. Inactivated or damaged? Comparing the effect
tionby β-propiolactone. Proteomics 13,3537–3547(2013).
87. She,Y.M.etal.Surfacemodificationsofinfluenzaproteinsuponvirusinactiv
tionsfortheinactivationofviruses. J.Biol.Chem. 286,36198–36214(2011).
propiolactone with nucleobase analogues, nucleosides, and peptides: implic
86. Uittenbogaard, J. P., Zomer, B., Hoogerhout, P. & Metz, B. Reactions of bet
tination,hemagglutination,andantigenicity. Appl.Microbiol. 19,290–294(1970
thiolate,andultravioletlightuponinfluenzavirusinfectivitychickencellaggl
85. Goldstein, M. A. & Tauraso, N. M. Effect of formalin, beta-propiolactone, me
59,1057–1062(2010).
seasonalinfluenza — UnitedStates,1976-2007. MMWRMorb.Mortal.WklyRe
84. Centers for Disease Control Prevention. Estimates of deaths associated wit
https://doi.org/10.1093/cid/ciaa1673(2020).
adjuvanted hemagglutinin nanoparticle influenza vaccine. Clin. Infect. Di
and polyfunctional CD4+ T-cell responses by a recombinant matrix-
83. Shinde,V.etal.Inductionofcross-reactivehemagglutinationinhibitingantibod
inadults65to74years,2017-2018. Vaccine 38,3121–3128(2020).
vanted,andrecombinantinfluenzavaccinesagainstcell-grownA(H3N2)viruse
82. Belongia,E.A.etal.Clinicaltrialtoassessimmunogenicityofhigh-dose,adj
placebo-controlledtrial. Vaccine 29,7733–7739(2011).
proteinvaccine (FluBlok(R)) against influenzain healthyadults:a randomize
81. Treanor,J.J.etal.Protectiveefficacyofatrivalentrecombinanthemagglutini
2176–2185(2006).
step closer to a recombinant protein-based influenza vaccine. Vaccine 2
80. Wang,K.etal.Expressionandpurificationofaninfluenzahemagglutinin–on
BMCInfect.Dis. 10,5(2010).
thecaseagedistributionandunusualtoxicityinpandemicnovelH1N1influenza
79. Reichert,T.etal.Doesglycosylationasamodifieroforiginalantigenicsinexplai
hemagglutininstalk-reactiveantibodiesinhumans. mBio 7,e01996–01915(2016
78. Nachbagauer,R.etal.Agedependenceandisotypespecificityofinfluenzaviru
Virol. https://doi.org/10.1128/JVI.01150-19(2019).
vaccineversussubunitinactivatedinfluenzavirusvaccine:acomparativestudy.
77. Henry,C.etal.Monoclonalantibodyresponsesafterrecombinanthemagglutini
2476–2481(2014).
strainprotectionagainstinfluenzavirusinfections. Proc.NatlAcad.Sci.USA 11
76. Chen,J.R.etal.Vaccinationofmonoglycosylatedhemagglutinininducescros
immuneresponse. Proc.NatlAcad.Sci.USA 106,18137–18142(2009).
75. Wang,C.C.etal.Glycansoninfluenzahemagglutininaffectreceptorbindingan
doms. Cell 171,258–258.e251(2017).
74. Chung,C.Y.etal.SnapShot:N-glycosylationprocessingpathwaysacrosskin
viralhemagglutinin. Vaccine 27,4325–4336(2009).
duction:influenceofhostcelllineandvirusstrainontheglycosylationpattern
73. Schwarzer,J.etal.Glycananalysisincellculture-basedinfluenzavaccinepr